ALDX
Aldeyra Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
- Aldeyra Therapeutics Receives EMA Orphan Drug Designation for ADX-2191 in Primary Large B-Cell Lymphomas of Immune-Privileged Sites, Including Primary Vitreoretinal LymphomaAug 29, 2025
- Aldeyra Therapeutics Receives Orphan Designation From European Medicines Agency For ADX-2191 In Treatment Of Inherited Retinal Dystrophies Including Retinitis PigmentosaJul 24, 2025
News
- Aldeyra announces PDUFA extension for Reproxalap dry eye disease NDADec 16, 2025
- Aldeyra Therapeutics receives orphan designation from European Medicines Agency for ADX-2191 for treatment of primary large B-cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphomaAug 29, 2025
- Aldeyra Therapeutics receives Fast Track designation for ADX‑2191 for treatment of retinitis pigmentosaAug 19, 2025
- Aldeyra Therapeutics receives orphan designation from European Medicines Agency for ADX-2191 in treatment of inherited retinal dystrophies including retinitis pigmentosaJul 24, 2025
- Aldeyra Therapeutics announces FDA acceptance for review of new drug application for reproxalap to treat dry eye diseaseJul 17, 2025